Lupus (SLE): Treatment Options, CAR-T Research and Stem Cell Therapy

What is lupus?

Systemic lupus erythematosus (SLE), usually called lupus, is a chronic autoimmune disease in which the immune system produces antibodies that attack the body’s own tissues. It can affect the skin, joints, kidneys, blood cells, brain, heart and lungs. It is far more common in women, often starting between ages 15 and 45, and is more common and often more severe in people of Asian, African and Hispanic descent. The NHS lupus page gives a clear overview.

Symptoms

• Severe fatigue
• Joint pain and swelling
• Butterfly-shaped rash over the cheeks and nose, and rashes after sun exposure
• Mouth ulcers and hair thinning
• Fevers and swollen glands
• Chest pain on breathing (pleurisy)
• Swelling of the legs or foamy urine if the kidneys are affected (lupus nephritis)
• Numbness or tingling (lupus neuropathy), headaches or memory problems

Symptoms typically come in flares with calmer periods between.

Causes

Lupus arises from a mix of genetic, hormonal and environmental factors:

• Inherited genes that affect immune regulation
• Female hormones (oestrogen)
• Triggers such as UV light, infections (for example Epstein–Barr virus), smoking and some medicines (drug-induced lupus)

Diagnosis

There is no single test. Rheumatologists combine symptoms, examination and tests, often using the EULAR/ACR classification criteria.

Test	Why it is done
ANA (antinuclear antibody)	Positive in nearly all people with SLE, but also in many healthy people
Anti-dsDNA and anti-Sm antibodies	More specific for lupus; anti-dsDNA tracks activity
Complement levels (C3, C4)	Often low during active disease
Full blood count	Low white cells, platelets or anaemia
Urine tests and kidney function	Detect lupus nephritis
Kidney biopsy	Classifies nephritis to guide treatment
Antiphospholipid antibodies	Blood clot and pregnancy risk

If you already have these reports, you can send them for a doctor review and discuss whether an additional program is appropriate, and how it fits with your rheumatologist’s plan.

Standard treatment

Standard care controls lupus for many people and is essential. Treatment is tailored to which organs are affected.

1. Hydroxychloroquine for almost everyone with SLE, unless not tolerated. It reduces flares and improves survival.
2. Corticosteroids at the lowest dose and shortest time possible.
3. Immunosuppressants: mycophenolate, azathioprine, methotrexate, cyclophosphamide for severe organ involvement.
4. Biologics: belimumab and anifrolumab are approved in many countries. Voclosporin and obinutuzumab have been added for lupus nephritis in some regions.
5. Sun protection, vaccinations, heart and bone health measures.
6. Kidney care, including dialysis or transplant for end-stage kidney disease.

Cellular therapies: what the research shows

CAR-T cell therapy

CAR-T cells are engineered immune cells that target B cells. In a small German study published in Nature Medicine (Mackensen et al., 2022) and a follow-up in the New England Journal of Medicine (Müller et al., 2024), people with severe, treatment-resistant lupus achieved drug-free remission after CD19 CAR-T therapy. These results attracted major attention, but:

• Patient numbers were small and follow-up is still short
• CAR-T requires chemotherapy conditioning and hospital care, with risks such as cytokine release syndrome
• It remains experimental and is available only through clinical trials

CAR-T is not part of our outpatient programs. If you are interested, ask your rheumatologist about trials, or search ClinicalTrials.gov.

Mesenchymal stem cells (MSCs)

Mesenchymal stromal cells can modulate immune responses. Open-label studies, mainly from China, have reported improved disease activity and kidney measures in some patients with refractory lupus after umbilical cord MSC infusions. However, a randomised double-blind placebo-controlled trial in lupus nephritis (Deng et al., Annals of the Rheumatic Diseases, 2017) found no added benefit of MSCs over standard immunosuppression. The overall evidence level is early and mixed.

Our stem cell therapy page explains how MSC treatments are prepared and given. Exosome therapy for autoimmune disease is at an earlier research stage still.

Regulatory status

No stem cell or CAR-T product is approved for lupus by the US FDA, the Australian TGA or the UK MHRA. Patients in the US, UK and Australia should ask their rheumatologist about trials first. The FDA warns about unapproved stem cell therapies.

Who may be a candidate, and who should not

May be considered for assessment:

• Confirmed SLE under the care of a rheumatologist
• Stable disease on standard therapy, with persistent symptoms such as fatigue or joint pain
• Willingness to continue all prescribed medicines
• Recent blood and urine tests showing no active organ-threatening disease

Not suitable:

• Active lupus nephritis, central nervous system lupus or another organ-threatening flare
• Active infection
• Pregnancy, or planning pregnancy soon
• Active cancer
• History of blood clots without specialist anticoagulation plan
• Anyone wanting to stop standard lupus treatment

Risks

• Infusion reactions such as fever, chills or headache
• Infection, especially alongside immunosuppression
• Blood clots (a particular concern with antiphospholipid antibodies)
• Possible triggering of a flare with travel stress, sun exposure or infection
• Unknown long-term effects

Cells are prepared in ISO 9001:2015-certified partner laboratories.

What a Bangkok program looks like

1. Send your reports. ANA, anti-dsDNA, complement, blood count, kidney function, urine tests and rheumatology letters.
2. Doctor review. You receive an honest view, including when we recommend staying with standard care only.
3. Assessment in Bangkok. Examination and up-to-date safety blood tests.
4. Treatment plan, if suitable, alongside your usual medicines.
5. Record sharing with your rheumatologist.

See how it works. Related reading: rheumatoid arthritis.

Aftercare

• Continue hydroxychloroquine and all lupus medicines
• Use high-factor sunscreen and protective clothing in Thailand’s strong sun
• Avoid strenuous activity for a few days
• Report fever, rash, chest pain, swelling or foamy urine promptly
• Keep regular blood and urine monitoring with your rheumatologist

Sources

• NHS: Lupus
• Mackensen A, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nature Medicine, 2022.
• Müller F, et al. CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up. New England Journal of Medicine, 2024.
• Deng D, et al. Randomised double-blind placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cells in lupus nephritis. Annals of the Rheumatic Diseases, 2017.
• U.S. FDA: Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes